Recognition and treatment of anemia in the setting of heart failure due to systolic left ventricular dysfunction

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 2, 2008, Pages 199-208

  Howlett, Jonathan G ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Anemia; Darbepoetin; Erythrocyte stimulating agent; Erythropoietin; Heart failure; Iron; Renal dysfunction

Indexed keywords

AMLODIPINE; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HEMOGLOBIN; IRON; LOSARTAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; VALSARTAN; ANTIANEMIC AGENT; DRUG DERIVATIVE;

BLOOD TRANSFUSION; BREAST CANCER; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; HEAD AND NECK CANCER; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART SIZE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IRON DEFICIENCY ANEMIA; IRON STORAGE; KIDNEY FAILURE; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MORTALITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEIZURE; SIDE EFFECT; TREATMENT DURATION; ANEMIA; CARDIOLOGY; HEART LEFT VENTRICLE FUNCTION;

ANEMIA; CARDIOLOGY; ERYTHROPOIETIN; HEART FAILURE; HEMATINICS; HUMANS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 40149089895     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.2.199     Document Type: Review

References (64)

1. Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin. Nephrol. 26(4), 296-306 (2006).
2. Anand I, McMurray JJ, Whitmore J et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 110(2), 149-154 (2004).
3. Anand IS, Kuskowski MA, Rector TS et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 112(8), 1121-1127 (2005).
4. Cleland JG, Swedberg K, Follath F et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur. Heart J. 24(5), 442-463 (2003).
5. Maggioni AP, Opasich C, Anand I et al. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J. Card. Fail. 11(2), 91-98 (2005).
6. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J. Am. Soc. Nephrol. 13(7), 1928-1936 (2002).
7. McCullough PA, Lepor NE. The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment. Rev. Cardiovasc. Med. 6(1), 1-10 (2005).
8. O'Meara E, Clayton T, McEntegart MB et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 113(7), 986-994 (2006).
9. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 107(2), 223-225 (2003).
10. Kosiborod M, Smith GL, Radford MJ, Foody JM, Krumholz HM. The prognostic importance of anemia in patients with heart failure. Am. J. Med. 114(2), 112-119 (2003).
11. McCullough PA, Lepor NE. Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. Rev. Cardiovasc. Med. 6(Suppl. 3), S4-S12 (2005).
12. Vaglio J, Safley DM, Rahman M et al. Relation of anemia at discharge to survival after acute coronary syndromes. Am. J. Cardiol. 96(4), 496-499 (2005).
13. Westenbrink BD, Visser FW, Voors AA et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur. Heart. J. 28(2), 166-171 (2007).
14. van der Meer P, Lipsic E, Westenbrink BD et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 112(12), 1743-1747 (2005).
15. Opasich C, Cazzola M, Scelsi L et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur. Heart J. 26(21), 2232-2237 (2005).
16. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103(16), 2055-2059 (2001).
17. Nanas JN, Matsouka C, Karageorgopoulos D et al. Etiology of anemia in patients with advanced heart failure. J. Am. Coll. Cardiol. 48(12), 2485-2489 (2006).
18. Parsi A, Kleber FX. Anaemia in heart failure: its diagnosis and management. Eur. J. Heart Fail. 5(1), 3-4 (2003).
19. Sandek A, Bauditz J, Swidsinski A et al. Altered intestinal function in patients with chronic heart failure. J. Am. Coll. Cardiol. 50(16), 1561-1569 (2007).
20. Androne AS, Katz SD, Lund L et al. Hemodilution is common in patients with advanced heart failure. Circulation 107(2), 226-229 (2003).
21. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the Prospective Randomized Amlodipine Survival Evaluation (PRAISE). J. Am. Coll. Cardiol. 41(11), 1933-1939 (2003).
22. Anker S. Severity of anemia and risk of death or heart failure hospitalization. J. Am. Coll. Cardiol. 43(Suppl. A), 842 (2004).
23. Kosiborod M, Curtis JP, Wang Y et al. Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. Arch. Intern. Med. 165(19), 2237-2244 (2005).
24. Kalra PR, Collier T, Cowie MR et al. Haemoglobin concentration and prognosis in new cases of heart failure. Lancet 362(9379), 211-212 (2003).
25. Alexander M, Grumbach K, Remy L, Rowell R, Massie BM. Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity. Am. Heart J. 137(5), 919-927 (1999).
26. Komajda M, Anker SD, Charlesworth A et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur. Heart J. 27(12), 1440-1446 (2006).
27. Heart Failure Society Of A. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J. Card. Fail. 12(1), E1-E2 (2006).
28. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart J. 26(11), 1115-1140 (2005).
29. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112(12), e154-c235 (2005).
30. Arnold JM, Howlett JG, Dorian P et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can. J. Cardiol 23(1), 21-45 (2007).
31. Bolger AP, Bartlett FR, Penston HS et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J. Am. Coll. Cardiol. 48(6), 1225-1227 (2006).
32. Toblli JE, Lombrana A. Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J. Am. Coll. Cardiol. 50(17), 1657-1665 (2007).
33. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107(2), 294-299 (2003).
34. Silverberg DS, Wexler D, Blum M et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J. Am. Coll. Cardiol. 35(7), 1737-1744 (2000).
35. Silverberg DS, Wexler D, Blum M et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol. Dial. Transplant. 18(1), 141-146 (2003).
36. Silverberg DS, Wexler D, Sheps D et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J. Am. Coll. Cardiol. 37(7), 1775-1780 (2001).
37. Palazzuoli A, Silverberg DS, Iovine F et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am. Heart J. 154(4), 645 e9-15 (2007).
38. Bahlmann FH, De Groot K, Spandau JM et al. Erythropoietin regulates endothelial progenitor cells. Blood 103(3), 921-926 (2004).
39. Parsa CJ, Kim J, Riel RU et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J. Biol. Chem. 279(20), 20655-20662 (2004).
40. van der Meer P, Lipsic E, Henning RH et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J. Am. Coll. Cardiol. 46(1), 125-133 (2005).
41. Westenbrink BD, Lipsic E, van der Meer P et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur. Heart J. 28(16), 2018-2027 (2007).
42. Kourea K, Parissis JT, Farmakis D et al. Effects of darbepoetin-α on plasma proinflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure. Atherosclerois DOI: 17991471 (2007) (Epub ahead of print).
43. Heeschen C, Aicher A, Lehmann R et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102(4), 1340-1346 (2003).
44. Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE Jr. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J. Am. Soc. Nephrol. 7(5), 763-773 (1996).
45. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined Phase I and II clinical trial. N. Engl. J. Med. 316(2), 73-78 (1987).
46. Lim VS, DeGowin RL, Zavala D et al. Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann. Intern. Med. 110(2), 108-114 (1989).
47. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339(9), 584-590 (1998).
48. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin α in chronic kidney disease. N. Engl. J. Med. 355(20), 2085-2098 (2006).
49. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355(20), 2071-2084 (2006).
50. Atabek U, Alvarez R, Pello MJ et al. Erythropoetin accelerates hematocrit recovery in post-surgical anemia. Am. Surg. 61(1), 74-77 (1995).
51. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin α in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J. Clin. Oncol. 23(25), 5960-5972 (2005).
52. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J. Clin. Oncol. 25(9), 1027-1032 (2007).
53. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J. Natl Cancer Inst. 98(10), 708-714 (2006).
54. Rizzo JD, Somerfield MR, Hagerty KL et al. Use of Epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update. J. Clin. Oncol. 26(1), 132-149 (2008).
55. Ponikowski P, Anker SD, Szachniewicz J et al. Effect of darbepoetin α on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 49(7), 753-762 (2007).
56. Coletta AP, Tin L, Loh PH, Clark AL, Cleland JG. Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin α, FERRIC-HF and KW-3902. Eur. J. Heart Fail. 8(5), 547-549 (2006).
57. Cleland JG, Coletta AP, Clark AL, Velavan P, Ingle L. Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: darbepoetin α study, ECHOS, and ASCOT-BPLA. Eur. J. Heart Fail. 7(5), 937-939 (2005).
58. van Veldhuisen DJ, Dickstein K, Cohen-Solal A et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin α in patients with heart failure and anaemia. Eur. Heart J. 28(18), 2208-2216 (2007).
59. Mix TC, Brenner RM, Cooper ME et al. Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am. Heart J. 149(3), 408-413 (2005).
60. Young JB AI, Diaz R et al. Reduction of events with Darbepoetin α in Heart Failure (RED-HF) Trial. J. Card. Fail. 12(Suppl. I), S77 (2006).
61. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362(9386), 782-788 (2003).
62. Braunwald E, Domanski MJ, Fowler SE et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 351(20), 2058-2068 (2004).
63. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 355(9215), 1582-1587 (2000).
64. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349(9054), 747-752 (1997).